Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Оценка риска при легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии
2019-03-28
SCID: 54.1/7y848v7d
Discuss with AI
chronic thromboembolic pulmonary hypertensionclinical worsening-free survivalpulmonary arterial hypertensionriociguatrisk stratification
Figures from the paper
Abstract (AI)
BACKGROUND: Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three abbreviated versions of this risk stratification model were previously evaluated in patients with pulmonary arterial hypertension (PAH) in the French, Swedish and COMPERA registries. Our objective was to investigate the three abbreviated risk stratification methods for patients with mostly prevalent PAH and chronic thromboembolic pulmonary hypertension (CTEPH), in patients from the PATENT-1/2 and CHEST-1/2 studies of riociguat. METHODS: Risk was assessed at baseline and at follow-up in PATENT-1 and CHEST-1. Survival and clinical worsening-free survival were assessed in patients in each risk group/strata. RESULTS: With all three methods, riociguat improved risk group/strata in patients with PAH after 12 weeks. The French non-invasive and Swedish/COMPERA methods discriminated prognosis for survival and clinical worsening-free survival at both baseline and follow-up. Furthermore, patients achieving one or more low-risk criteria or a low-risk stratum at follow-up had a significantly reduced risk of death and clinical worsening compared with patients achieving no low-risk criteria or an intermediate-risk stratum. Similar results were obtained in patients with inoperable or persistent/recurrent CTEPH. CONCLUSIONS: This analysis confirms and extends the results of the registry analyses, supporting the value of goal-oriented treatment in PAH. Further assessment of these methods in patients with CTEPH is warranted.
Key Findings
1
After 12 weeks, riociguat improved risk groups or strata in patients with PAH across all three assessment methods.
2
Patients achieving at least one low-risk criterion or a low-risk stratum at follow-up had significantly lower risks of death and clinical worsening than patients without low-risk criteria or in intermediate-risk strata.
3
Similar prognostic associations were observed in patients with inoperable or persistent/recurrent CTEPH, supporting goal-oriented treatment while warranting further CTEPH validation.
4
The French non-invasive and Swedish/COMPERA methods discriminated survival and clinical worsening-free survival at baseline and follow-up.
5
Three abbreviated pulmonary hypertension risk-stratification methods were evaluated in predominantly prevalent PAH and CTEPH patients from the PATENT and CHEST riociguat studies.
Research Object
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) treated with riociguat
Research Subject
The prognostic discrimination and treatment-related changes of abbreviated risk stratification methods, including associations with survival and clinical worsening-free survival
Publication Details
Publication Date
2019-03-28
Journal
Publisher
ISSN
Cited by
113
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
Risk stratification and medical therapy of pulmonary arterial hypertension2018
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model2017
Cited by4
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022
Risk stratification and treatment goals in pulmonary arterial hypertension2024
Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival2020
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022